Clinical Trial Update: A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing durvalumab and tremelimumab as monotherapy or in combination (durvalumab plus tremelimumab) or with bevacizumab in advanced hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-12-06